A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma Clinical Trial

Official title:

An Open-label, Single-arm, Single-center, Phase II Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate for Injection in Subjects With HER2-negative Metastatic or Unresectable Urothelial Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04073602
• Other study ID #: RC48-C011
• Status: Completed
• Phase: Phase 2
• Start date: August 19, 2019
• Est. completion date: January 31, 2023

Study information

• Verified date: December 2023
• Source: RemeGen Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy and safety of intravenous RC48-ADC in patients with locally advanced or metastatic HER2-negative urothelial cancer.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 19
• Est. completion date: January 31, 2023
• Est. primary completion date: September 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Voluntary agreement to provide written informed consent.

• Male or female, Age = 18 years.

• Predicted survival = 12 weeks.

• Diagnosed with histologically or cytologically-confirmed locally advanced or metastatic urothelial cancer, originate from bladder, renal pelvis, ureter and urinary tract.

• Unresectable or disease progression (i.e. locally advanced/metastasis) after surgery and at least regular chemotherapy including gemcitabine, cisplatin AND paclitaxel. Disease progression within 6 months of the completion of neo-adjuvant and adjuvant chemotherapy with gemcitabine, cisplatin AND paclitaxel is also eligible.

• Measurable lesion according to RECIST 1.1.

• HER2 negative (i.e. IHC -or 1+) as confirmed by the department of Pathology in Beijing Cancer Hospital. Subject is able to provide specimens from primary or metastatic lesions for HER2 tests.

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.

• Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment:

Cardiac ejection fraction = 50 %. Hemoglobin = 9g/dL; Absolute neutrophil count = 1.5×10^9/L Platelets = 100×10^9/L; Total bilirubin = 1.5× ULN; AST and ALT = 2.5×ULN and = 5 x ULN with hepatic metastasis; Serum creatinine =1.5×ULN.

• All female subjects will be considered to be of child-bearing potential unless they are postmenopausal, or have been sterilized surgically.Female subjects of child-bearing potential must agree to use two forms of highly effective contraception. Male subjects and their female partner who are of child-bearing potential must agree to use two forms of highly effective contraception.

• Willing to adhere to the study visit schedule and the prohibitions and restrictions specified in this protocol.

Exclusion Criteria:

• Known hypersensitivity to the components of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate.

• Toxicity of previous anti-tumor treatment not recovered to CTCAE Grade 0-1 (with exception of Grade 2 alopecia).

• Pleural or abdominal effusion with clinical symptoms that requires ongoing treatment.

• History of receiving any anti-cancer drug/biologic treatment within 3 weeks prior to trial treatment.

• History of major surgery within 4 weeks of planned start of trial treatment.

• Has received a live virus vaccine within 4 weeks of planned start of trial treatment.

• Currently known active infection with HIV or tuberculosis.

• Diagnosed with HBsAg , HBcAb positive and HBV DNA copy positive, or HCVAb positive.

• Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.

• History of other malignancy within the previous 3 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or cancers with a similar curative outcome as those mentioned above.

• known central nervous system metastases.

• Uncontrolled hypertension, diabetes, Interstitial lung Disease, or COPD;

• Treated with systemic treatment (e.g. immunomodulators, corticosteroids or immunosuppressants) for the autoimmune disease within 2 years prior to the study treatment.

• NYHA Class III heart failure

• Pregnancy or lactation.

• Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.

Related Conditions & MeSH terms

• Carcinoma, Transitional Cell
• Urothelial Carcinoma

Intervention

Drug:
• RC48-ADC
The eligible patients will be treated with RC48-ADC, an antibody-drug conjugate, 2.0 mg/kg, once every two weeks until investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
RemeGen Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR)as assessed by Investigator	Objective Response Rate was defined as the percentage of participants with a complete response (CR) or partial response (PR)	24 months
Secondary	Progression Free Survival (PFS)	Tumor response was assessed by investigator according to RECIST v1.1	24 months
Secondary	Duration of Objective Response (DOR)	DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier	24 months
Secondary	Disease control rate (DCR)	DCR was defined as the proportion of patients who achieved an objective response or maintained stable disease during the study	24 months
Secondary	Overall Survival(OS)	OS was defined as the time from the first study treatment to the date of death from any cause.	up to 24 months
Secondary	Adverse Events	Incidence of Adverse Events	28 days after the last dose of study treatment